Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aminoglycosides and Protective Isolation in Neutropenic Sepsis
NCT05443854Phase 3Unknown
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of amikacin in sepsis and septic shock (4 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Mortality at Day 90. Status: unknown.
02
Drugs
amikacin
03
Conditions
sepsisseptic shock
Beyond the preview
Go deeper on NCT05443854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05443854.